Portal de Periódicos da CAPES

Safety of Typhim Vi Vaccine in a Postmarketing Observational Study

2007; Oxford University Press; Volume: 14; Issue: 6 Linguagem: Inglês

10.1111/j.1708-8305.2007.00158.x

1708-8305

Leonard C. Marcus, James E. Froeschle, David R. Hill, Martin S. Wolfe, Diane Maus, Bradley A. Connor, Alberto Acosta, Edward R. Rensimer, Alan Roberts, Kenneth R. Dardick,

Hepatitis Viruses Studies and Epidemiology

BackgroundTyphoid fever is endemic in many parts of the world. In the United States, nearly three quarters of all cases are contracted by persons who traveled to regions with endemic disease. Typhim Vi, a vaccine containing the purified cell surface Vi polysaccharide of the Salmonella enterica serovar Typhi, was developed to provide protection against typhoid fever. We present the results of the largest safety study of this Vi vaccine to date.